市場調查報告書

鐮狀細胞貧血(SCD)- 市場洞察,流行病學,市場預測 2028年

Sickle Cell Disease (SCD) - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 534846
出版日期 內容資訊 英文 165 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
鐮狀細胞貧血(SCD)- 市場洞察,流行病學,市場預測 2028年 Sickle Cell Disease (SCD) - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年11月01日內容資訊: 英文 165 Pages
簡介

新興7個國家(土耳其、沙烏地阿拉伯、阿拉伯聯合大公國、墨西哥、哥倫比亞、巴西、阿根廷)的鐮狀細胞貧血(SCD)的2017年的患病數為14萬3,306人,同年的市場規模估算為約3億8,544萬美元。

本報告提供新興7個國家(土耳其,沙烏地阿拉伯,阿拉伯聯合大公國,墨西哥,哥倫比亞,巴西,阿根廷)的鐮狀細胞貧血(SCD)市場調查,疾病概要和現行的治療方法,已上市治療藥及新藥的簡介,以整體及各國的市場趨勢,流行病學的預測,市場規模,各病型、臨床症狀的患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 簡介

第2章 鐮狀細胞貧血(SCD)市場概要

  • 鐮狀細胞貧血(SCD)的市場佔有率(成果值)
  • 鐮狀細胞貧血(SCD)的市場佔有率(預測值)

第3章 疾病背景和概要:鐮狀細胞貧血(SCD)

  • 簡介
  • 區分
  • 病因
  • 風險要素
  • 併發症
  • 症狀
  • 病理生理學
  • 診斷

第4章 新興7個國家的總患病數

  • 主要調查結果
  • 新興7個國家的總患病數
  • 新興7個國家的診斷患病數

第5章 鐮狀細胞貧血(SCD)的流行病學:各國

  • 假設和理論的根據
  • 沙烏地阿拉伯
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 阿拉伯聯合大公國(UAE)
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 土耳其
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 墨西哥
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 巴西
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 阿根廷
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 哥倫比亞
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀

第6章 鐮狀細胞貧血(SCD)的治療和管理

  • 血管閉塞症
  • 慢性疾病
  • 其他有潛力治療方法

第7章 未滿足需求

第8章 已上市治療藥

  • Droxia:Bristol-Myers Squibb
    • 醫藥品概要
    • 法規的里程碑
    • 安全性和有效性
    • 產品簡介
  • Endari:Emmaus Life Sciences, Inc.

第9章 新藥

  • Crizanlizumab:Novartis Pharmaceuticals
    • 醫藥品概要
    • 開發趨勢
    • 臨床趨勢
    • 安全性和有效性
    • 產品簡介
  • Rivipansel:Pfizer Inc.
  • GBT 440:Global Blood Therapeutics, Inc.
  • SC411 (Altemia):Micelle BioPharma Inc.
  • Ticagrelor:AstraZeneca
  • LentiGlobin BB305:BlueBird Bio
  • Olinciguat:Cyclerion Therapeutics

第10章 有潛力候補藥

  • BIVV003:Sanofi (Bioverativ Inc.)
    • 醫藥品概要
    • 開發趨勢
    • 臨床趨勢
    • 產品簡介
  • IMR-687:Imara Inc.
  • CTX001:CRISPR Therapeutics
  • Sevuparin:Modus Therapeutics

第11章 新興7個國家的鐮狀細胞貧血(SCD)市場分析

  • 主要調查結果
  • 新興7個國家的市場規模
  • 新興7個國家的市場規模:各治療藥物

第12章 新興7個國家的鐮狀細胞貧血(SCD)市場預測

  • 市場概要
  • 沙烏地阿拉伯
    • 市場規模
    • 市場規模:各治療藥物
  • 阿拉伯聯合大公國(UAE)
  • 土耳其
  • 墨西哥
  • 巴西
  • 阿根廷
  • 哥倫比亞

第13章 市場成長要素

第14章 市場障礙

第15章 附錄

第16章 DelveInsight的服務內容

第17章 免責聲明

第18章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0211

DelveInsight's 'Sickle Cell Disease (SCD) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SCD in the 7 Emerging Markets (EM) ,i.e., Turkey, , Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Sickle Cell Disease (SCD) from 2017 to 2028 segmented by seven emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • Middle East (Turkey, Saudi Arabia , UAE)
  • Latin America (Mexico, Colombia, Brazil, Argentina)

Study Period: 2017-2028

Sickle Cell Disease (SCD) - Disease Understanding

Sickle cell disease (SCD) is a group of inherited disorders caused by mutations in HBB, which encodes haemoglobin subunit B. Haemoglobin molecules that include mutant sickle B globin subunits can polymerize; erythrocytes that contain mostly haemoglobin polymers assume a sickled form and are prone to haemolysis. Other pathophysiological mechanisms that contribute to the SCD phenotype are vaso-occlusion and activation of the immune system. SCD is characterized by a remarkable phenotypic complexity. Common acute complications are acute pain events, acute chest syndrome and stroke; chronic complications.

The DelveInsight Sickle cell disease (SCD) market report gives the thorough understanding of the Sickle cell disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms for Sickle cell disease in the 7EM.

Sickle Cell Disease Epidemiology

The Sickle Cell Disease (SCD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven countries in the report. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalence of Sickle Cell Disease in 7 EM, diagnosed prevalence of Sickle Cell Disease in 7 EM) scenario of Sickle Cell Disease (SCD) in the 7EM covering Turkey, , Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina from 2017-2028.

According to DelveInsight, Total prevalent population of Sickle Cell Disease in 7 EM was observed to be 143,306 cases in 2017.

Sickle Cell Disease Drug Chapters

This segment of the Sickle Cell Disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Drugs targeting either red cell or leukocyte adhesion (or both) are attractive therapeutic modalities in treating SCD, because multiple adhesive interactions have been demonstrated as contributing to vaso-occlusion. Drugs targeting selectin-mediated adhesion are being especially actively investigated.

Sickle Cell Disease Market Outlook

The Sickle Cell Disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Sickle Cell Disease in 7EM was found to be USD 385.44 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Brazil accounts for the largest market size of Sickle Cell Disease, in comparison to the other 7 Emerging Markets i.e., Turkey, Saudi Arabia, UAE, Mexico, Colombia, and Argentina.

Sickle Cell Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Sickle Cell Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Sickle Cell Disease Report Key Strengths

  • 10 Years Forecast
  • 7EM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Sickle Cell Disease Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Sickle Cell Disease market
  • Organize sales and marketing efforts by identifying the best opportunities for Sickle Cell Disease market
  • To understand the future market competition in the Sickle Cell Disease market.

Table of Contents

1. Key Insights

2. Sickle Cell Disease Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Sickle Cell Disease in 2017
  • 2.2. Market Share (%) Distribution of Sickle Cell Disease in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Classification of Sickle Cell Disease
  • 3.3. Causes
  • 3.4. Associated risk factors
  • 3.5. Complications
  • 3.6. Symptoms
  • 3.7. Pathophysiology
  • 3.8. Diagnosis

4. Seven Emerging Markets (EM) Total Prevalent Patient Population of Sickle Cell Disease (SCD)

  • 4.1. Key Findings
  • 4.2. Total Prevalence of Sickle Cell Disease in 7 Emerging Markets
  • 4.3. Diagnosed Prevalence of Sickle Cell Disease in 7 Emerging Markets

5. Country Wise-Epidemiology of Sickle Cell Disease (SCD)

  • 5.1. Emerging Markets: Assumptions and Rationale
  • 5.2. Saudi Arabia
    • 5.2.1. Total Prevalent Cases of SCD trait in Saudi Arabia
    • 5.2.2. Total Prevalent Cases of SCD in Saudi Arabia
    • 5.2.3. Diagnosed Cases of SCD in Saudi Arabia
    • 5.2.4. Type-specific prevalence of SCD in Saudi Arabia
    • 5.2.5. Clinical manifestations of SCD in Saudi Arabia
  • 5.3. U.A.E.
    • 5.3.1. Total Prevalent Cases of SCD trait in U.A.E.
    • 5.3.2. Total Prevalent Cases of SCD in U.A.E.
    • 5.3.3. Diagnosed Cases of SCD in U.A.E.
    • 5.3.4. Type-specific prevalence of SCD in U.A.E.
    • 5.3.5. Clinical manifestations of SCD in U.A.E.
  • 5.4. Turkey
    • 5.4.1. Total Prevalent Cases of SCD trait in Turkey
    • 5.4.2. Total Prevalent Cases of SCD in Turkey
    • 5.4.3. Diagnosed Cases of SCD in Turkey
    • 5.4.4. Type-specific prevalence of SCD in Turkey
    • 5.4.5. Clinical manifestations of SCD in Turkey
  • 5.5. Mexico
    • 5.5.1. Total Prevalent Cases of SCD trait in Mexico
    • 5.5.2. Total Prevalent Cases of SCD in Mexico
    • 5.5.3. Diagnosed Cases of SCD in Mexico
    • 5.5.4. Type-specific prevalence of SCD in Mexico
    • 5.5.5. Clinical manifestations of SCD in Mexico
  • 5.6. Brazil
    • 5.6.1. Total Prevalent Cases of SCD trait in Brazil
    • 5.6.2. Total Prevalent Cases of SCD in Brazil
    • 5.6.3. Diagnosed Cases of SCD in Brazil
    • 5.6.4. Type-specific prevalence of SCD in Brazil
    • 5.6.5. Clinical manifestations of SCD in Brazil
  • 5.7. Argentina
    • 5.7.1. Total Prevalent Cases of SCD trait in Argentina
    • 5.7.2. Total Prevalent Cases of SCD in Argentina
    • 5.7.3. Diagnosed Cases of SCD in Argentina
    • 5.7.4. Type-specific prevalence of SCD in Argentina
    • 5.7.5. Clinical manifestations of SCD in Argentina
  • 5.8. Colombia
    • 5.8.1. Total Prevalent Cases of SCD trait in Colombia
    • 5.8.2. Total Prevalent Cases of SCD in Colombia
    • 5.8.3. Diagnosed Cases of SCD in Colombia
    • 5.8.4. Type-specific prevalence of SCD in Colombia
    • 5.8.5. Clinical manifestations of SCD in Colombia

6. Treatment and Management of Sickle Cell Disease

  • 6.1. Vaso-occlusive crisis
  • 6.2. Chronic disease
  • 6.3. Other promising therapeutic approaches

7. Unmet Needs

8. Marketed drugs

  • 8.1. Droxia: Bristol-Myers Squibb
    • 8.1.1. Product Description
    • 8.1.2. Regulatory Milestones
    • 8.1.3. Safety and Efficacy
    • 8.1.4. Product Profile
  • 8.2. Endari: Emmaus Life Sciences, Inc.
    • 8.2.1. Product Description
    • 8.2.2. Regulatory Milestones
    • 8.2.3. Other Developmental Activities
    • 8.2.4. Safety and Efficacy
    • 8.2.5. Product Profile

9. Emerging Therapies

  • 9.1. Crizanlizumab: Novartis Pharmaceuticals
    • 9.1.1. Product Description
    • 9.1.2. Product Development Activities
    • 9.1.3. Clinical development
    • 9.1.4. Safety and Efficacy
    • 9.1.5. Product Profile
  • 9.2. Rivipansel: Pfizer Inc.
    • 9.2.1. Product Description
    • 9.2.2. Product Development Activities
    • 9.2.3. Clinical development
    • 9.2.4. Safety and Efficacy
    • 9.2.5. Product Profile
  • 9.3. GBT 440: Global Blood Therapeutics, Inc.
    • 9.3.1. Product Description
    • 9.3.2. Product Development Activities
    • 9.3.3. Clinical development
    • 9.3.4. Safety and Efficacy
    • 9.3.5. Product Profile
  • 9.4. SC411 (Altemia): Micelle BioPharma Inc.
    • 9.4.1. Product Description
    • 9.4.2. Product Development Activities
    • 9.4.3. Clinical development
    • 9.4.4. Safety and Efficacy
    • 9.4.5. Product Profile
  • 9.5. Ticagrelor: AstraZeneca
    • 9.5.1. Product Description
    • 9.5.2. Clinical development
    • 9.5.3. Safety and Efficacy
    • 9.5.4. Product Profile
  • 9.6. LentiGlobin BB305: BlueBird Bio
    • 9.6.1. Product Description
    • 9.6.2. Other Development Activities
    • 9.6.3. Clinical Development
    • 9.6.4. Safety and Efficacy
    • 9.6.5. Product Profile
  • 9.7. Olinciguat: Cyclerion Therapeutics
    • 9.7.1. Product Description
    • 9.7.2. Product Development Activities
    • 9.7.3. Clinical Development
    • 9.7.4. Safety and Efficacy
    • 9.7.5. Product Profile

10. Other promising candidates

  • 10.1. BIVV003: Sanofi (Bioverativ Inc.)
    • 10.1.1. Product Description
    • 10.1.2. Product Development Activities
    • 10.1.3. Clinical development
    • 10.1.4. Product Profile
  • 10.2. IMR-687: Imara Inc.
    • 10.2.1. Product Description
    • 10.2.2. Product Development Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Safety and Efficacy
    • 10.2.5. Product Profile
  • 10.3. CTX001: CRISPR Therapeutics
    • 10.3.1. Product Description
    • 10.3.2. Product Development Activities
    • 10.3.3. Clinical Development
    • 10.3.4. Safety and Efficacy
    • 10.3.5. Product Profile
  • 10.4. Sevuparin: Modus Therapeutics
    • 10.4.1. Product Description
    • 10.4.2. Product Development Activities
    • 10.4.3. Clinical Development
    • 10.4.4. Safety and Efficacy
    • 10.4.5. Product Profile

11. Sickle Cell Disease: 7 EM Analysis

  • 11.1. Key Findings
  • 11.2. Market Size of SCD in 7 EM
    • 11.2.1. Market Size of SCD by Therapies

12. Market Outlook by Country

  • 12.1. Emerging Markets: Market Outlook
  • 12.2. Saudi Arabia
    • 12.2.1. Total Market Size of SCD
    • 12.2.2. Market Size of SCD by Therapies
  • 12.3. U.A.E.
    • 12.3.1. Total Market Size of SCD
    • 12.3.2. Market Size of SCD by Therapies
  • 12.4. Turkey
    • 12.4.1. Total Market Size of SCD
    • 12.4.2. Market Size of SCD by Therapies
  • 12.5. Mexico
    • 12.5.1. Total Market Size of SCD
    • 12.5.2. Market Size of SCD by Therapies
  • 12.6. Brazil
    • 12.6.1. Total Market Size of SCD
    • 12.6.2. Market Size of SCD by Therapies
  • 12.7. Argentina
    • 12.7.1. Total Market Size of SCD
    • 12.7.2. Market Size of SCD by Therapies
  • 12.8. Colombia
    • 12.8.1. Total Market Size of SCD
    • 12.8.2. Market Size of SCD by Therapies

13. Market Drivers

14. Market Barriers

15. Appendix

  • 15.1. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables

  • Table 1: Laboratory test schedule for patients with SCD
  • Table 2: Total Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Table 3: Diagnosed Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Table 4: Total Prevalent Cases of SCD trait in Saudi Arabia (2017-2028)
  • Table 5: Total Prevalent Cases of SCD in Saudi Arabia (2017-2028)
  • Table 6: Total Diagnosed Cases of SCD in Saudi Arabia (2017-2028)
  • Table 7: Type-specific prevalence of SCD in Saudi Arabia (2017-2028)
  • Table 8: Clinical manifestations of SCD in Saudi Arabia (2017-2028)
  • Table 9: Total Prevalent Cases of SCD trait in U.A.E. (2017-2028)
  • Table 10: Total Prevalent Cases of SCD in U.A.E. (2017-2028)
  • Table 11: Total Diagnosed Cases of SCD in U.A.E. (2017-2028)
  • Table 12: Type-specific prevalence of SCD in U.A.E. (2017-2028)
  • Table 13: Clinical manifestations of SCD in U.A.E. (2017-2028)
  • Table 14: Total Prevalent Cases of SCD trait in Turkey (2017-2028)
  • Table 15: Total Prevalent Cases of SCD in Turkey (2017-2028)
  • Table 16: Total Diagnosed Cases of SCD in Turkey (2017-2028)
  • Table 17: Type-specific prevalence of SCD in Turkey (2017-2028)
  • Table 18: Clinical manifestations of SCD in Turkey (2017-2028)
  • Table 19: Total Prevalent Cases of SCD trait in Mexico (2017-2028)
  • Table 20: Total Prevalent Cases of SCD in Mexico (2017-2028)
  • Table 21: Total Diagnosed Cases of SCD in Mexico (2017-2028)
  • Table 22: Type-specific prevalence of SCD in Mexico (2017-2028)
  • Table 23: Clinical manifestations of SCD in Mexico (2017-2028)
  • Table 24: Total Prevalent Cases of SCD trait in Brazil (2017-2028)
  • Table 25: Total Prevalent Cases of SCD in Brazil (2017-2028)
  • Table 26: Total Diagnosed Cases of SCD in Brazil (2017-2028)
  • Table 27: Type-specific prevalence of SCD in Brazil (2017-2028)
  • Table 28: Clinical manifestations of SCD in Brazil (2017-2028)
  • Table 29: Total Prevalent Cases of SCD trait in Argentina (2017-2028)
  • Table 30: Total Prevalent Cases of SCD in Argentina (2017-2028)
  • Table 31: Total Diagnosed Cases of SCD in Argentina (2017-2028)
  • Table 32: Type-specific prevalence of SCD in Argentina (2017-2028)
  • Table 33: Clinical manifestations of SCD in Argentina (2017-2028)
  • Table 34: Total Prevalent Cases of SCD trait in Colombia (2017-2028)
  • Table 35: Total Prevalent Cases of SCD in Colombia (2017-2028)
  • Table 36: Total Diagnosed Cases of SCD in Colombia (2017-2028)
  • Table 37: Type-specific prevalence of SCD in Colombia (2017-2028)
  • Table 38: Clinical manifestations of SCD in Colombia (2017-2028)
  • Table 39: Pharmacological management of pain using WHO three step "Analgesic Ladder"
  • Table 40: Nonnarcotic Analgesics for Mild Pain in Sickle Cell Disease
  • Table 41: Outline of management of acute pain in opioid naive adults
  • Table 42: Outline of management of acute pain in opioid naive adults
  • Table 43: Outline of management of acute pain in opioid naive adults
  • Table 44: Outline of management of acute pain in opioid naive adults
  • Table 45: LentiGlobin BB305, Clinical Trial Description 2019
  • Table 46: Total Market Size of SCD in 10 Emerging Markets in USD Million (2017-2028)
  • Table 47: Total Market Size of SCD by Therapies in 10 Emerging Markets in USD Million (2017-2028)
  • Table 48: Market Size of SCD in the Saudi Arabia, USD Million (2017-2028)
  • Table 49: Total Market Size of SCD by Therapies in Saudi Arabia in USD Million (2017-2028)
  • Table 50: Market Size of SCD in U.A.E., USD Million (2017-2028)
  • Table 51: Total Market Size of SCD by Therapies in U.A.E. in USD Million (2017-2028)
  • Table 52: Market Size of SCD in Turkey, USD Million (2017-2028)
  • Table 53: Total Market Size of SCD by Therapies in Turkey in USD Million (2017-2028)
  • Table 54: Market Size of SCD in Mexico, USD Million (2017-2028)
  • Table 55: Total Market Size of SCD by Therapies in Mexico in USD Million (2017-2028)
  • Table 56: Market Size of SCD in Brazil, USD Million (2017-2028)
  • Table 57: Total Market Size of SCD by Therapies in Brazil in USD Million (2017-2028)
  • Table 58: Market Size of SCD in Argentina, USD Million (2017-2028)
  • Table 59: Total Market Size of SCD by Therapies in Argentina in USD Million (2017-2028)
  • Table 60: Market Size of SCD in Colombia, USD Million (2017-2028)
  • Table 61: Total Market Size of SCD by Therapies in Colombia in USD Million (2017-2028)

List of Figures

  • Figure 1: Sickle Cell Disease classification
  • Figure 2: SCD complications
  • Figure 3: Common symptoms associated with Sickle Cell Disease
  • Figure 4: Induction of Red-Cell Sickling by Polymerization of Deoxy-hemoglobin-S
  • Figure 5: Principal Mechanisms Responsible for Potassium and Water Loss in Sickle Red Cells.
  • Figure 6: Principal Interactions Responsible for the Adhesion of a Sickle Red Cell to the Microvascular Endothelium
  • Figure 7: Total Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Figure 8: Diagnosed Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Figure 9: Total Prevalent Cases of SCD trait in Saudi Arabia (2017-2028)
  • Figure 10: Total Prevalent Cases of SCD in Saudi Arabia (2017-2028)
  • Figure 11: Total Diagnosed Cases of SCD in Saudi Arabia (2017-2028)
  • Figure 12: Type-specific prevalence of SCD in Saudi Arabia (2017-2028)
  • Figure 13: Clinical manifestations of SCD in Saudi Arabia (2017-2028)
  • Figure 14: Total Prevalent Cases of SCD trait in U.A.E. (2017-2028)
  • Figure 15: Total Prevalent Cases of SCD in U.A.E. (2017-2028)
  • Figure 16: Total Diagnosed Cases of SCD in U.A.E. (2017-2028)
  • Figure 17: Type-specific prevalence of SCD in U.A.E. (2017-2028)
  • Figure 18: Clinical manifestations of SCD in U.A.E. (2017-2028)
  • Figure 19: Total Prevalent Cases of SCD trait in Turkey (2017-2028)
  • Figure 20: Total Prevalent Cases of SCD in Turkey (2017-2028)
  • Figure 21: Total Diagnosed Cases of SCD in Turkey (2017-2028)
  • Figure 22: Type-specific prevalence of SCD in Turkey (2017-2028)
  • Figure 23: Clinical manifestations of SCD in Turkey (2017-2028)
  • Figure 24: Total Prevalent Cases of SCD trait in Mexico (2017-2028)
  • Figure 25: Total Prevalent Cases of SCD in Mexico (2017-2028)
  • Figure 26: Total Diagnosed Cases of SCD in Mexico (2017-2028)
  • Figure 27: Type-specific prevalence of SCD in Mexico (2017-2028)
  • Figure 28: Clinical manifestations of SCD in Mexico (2017-2028)
  • Figure 29: Total Prevalent Cases of SCD trait in Brazil (2017-2028)
  • Figure 30: Total Prevalent Cases of SCD in Brazil (2017-2028)
  • Figure 31: Total Diagnosed Cases of SCD in Brazil (2017-2028)
  • Figure 32: Type-specific prevalence of SCD in Brazil (2017-2028)
  • Figure 33: Clinical manifestations of SCD in Brazil (2017-2028)
  • Figure 34: Total Prevalent Cases of SCD trait in Argentina (2017-2028)
  • Figure 35: Total Prevalent Cases of SCD in Argentina (2017-2028)
  • Figure 36: Total Diagnosed Cases of SCD in Argentina (2017-2028)
  • Figure 37: Type-specific prevalence of SCD in Argentina (2017-2028)
  • Figure 38: Clinical manifestations of SCD in Argentina (2017-2028)
  • Figure 39: Total Prevalent Cases of SCD trait in Colombia (2017-2028)
  • Figure 40: Total Prevalent Cases of SCD in Colombia (2017-2028)
  • Figure 41: Total Diagnosed Cases of SCD in Colombia (2017-2028)
  • Figure 42: Type-specific prevalence of SCD in Colombia (2017-2028)
  • Figure 43: Clinical manifestations of SCD in Colombia (2017-2028)
  • Figure 44 Treatment algorithm for SCD
  • Figure 45 Measure of pain intensity and location
  • Figure 46: Schematic diagram of the mechanisms of action of pathophysiology based new therapeutic options for treatment of Sickle Cell Disease
  • Figure 47: Unmet needs for Sickle Cell Disease
  • Figure 48: Total Market Size of SCD in 10 Emerging Markets in USD Million (2017-2028)
  • Figure 49: Total Market Size of SCD by Therapies in 10 Emerging Markets in USD Million (2017-2028)
  • Figure 50: Market Size of SCD in the Saudi Arabia, USD Million (2017-2028)
  • Figure 51: Saudi Arabia Market Size of SCD by Therapies in USD Million (2017-2028)
  • Figure 52: Market Size of SCD in U.A.E., USD Million (2017-2028)
  • Figure 53: U.A.E. Market Size of SCD by Therapies in USD Million (2017-2028)
  • Figure 54: Market Size of SCD in Turkey, USD Million (2017-2028)
  • Figure 55: Turkey Market Size of SCD by Therapies in USD Million (2017-2028)
  • Figure 56: Market Size of SCD in Mexico, USD Million (2017-2028)
  • Figure 57: Mexico Market Size of SCD by Therapies in USD Million (2017-2028)
  • Figure 58: Market Size of SCD in Brazil, USD Million (2017-2028)
  • Figure 59: Brazil Market Size of SCD by Therapies in USD Million (2017-2028)
  • Figure 60: Market Size of SCD in Argentina, USD Million (2017-2028)
  • Figure 61: Argentina Market Size of SCD by Therapies in USD Million (2017-2028)
  • Figure 62: Market Size of SCD in Colombia, USD Million (2017-2028)
  • Figure 63: Colombia Market Size of SCD by Therapies in USD Million (2017-2028)
  • Figure 64: Market drivers for Sickle Cell Disease
  • Figure 65: Market barriers for Sickle Cell Disease
Back to Top